Minerva Neurosciences is a leading biotech company based in Waltham, MA, specializing in the development of innovative treatments for central nervous system disorders. With a strong focus on clinical development, their expertise lies in designing trials with patient-centric endpoints, aiming to provide direct benefits to individuals suffering from conditions such as schizophrenia and Parkinson's disease.
Driven by a commitment to innovation, Minerva Neurosciences boasts an impressive pipeline of product candidates, including Roluperidone, MIN-101, MIN-301, and Seltorexant. By leveraging their clinical expertise and patient-focused approach, they strive to improve the lives of those affected by neurological disorders, making significant contributions to the field of neuroscience.
Generated from the website